February 12, 2018 / 1:30 PM / 5 days ago

BRIEF-MabVax Therapeutics Announces Positive Interim Data From Trial of MVT-5873

Feb 12 (Reuters) - MabVax Therapeutics Holdings Inc :

* MABVAX THERAPEUTICS ANNOUNCES POSITIVE INTERIM DATA FROM EXPANDED COHORT IN PHASE 1 TRIAL EVALUATING MVT-5873 IN COMBINATION WITH FIRST-LINE CHEMOTHERAPY IN PANCREATIC CANCER

* MABVAX THERAPEUTICS HOLDINGS - ‍MVT-5873 AT A DOSE OF 0.125 MG/KG WHEN ADDED TO FIRST-LINE CHEMOTHERAPY WAS GENERALLY WELL TOLERATED BY ALL SUBJECTS​

* MABVAX THERAPEUTICS HOLDINGS INC - ‍COMPANY PLANS TO ENROLL ADDITIONAL PATIENTS AT THIS DOSE TO FURTHER EXPLORE SAFETY AND POTENTIAL RESPONSE​

* MABVAX THERAPEUTICS HOLDINGS INC - ‍AT DOSE TESTED, ALL SIX PATIENTS IN COHORT HAD MEANINGFUL REDUCTIONS IN TUMOR VOLUME BY RECIST​ Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below